Braeburn Pharmaceuticals and Camurus Enroll First Patients in a Phase 3 Efficacy Trial of CAM2038 for treatment of Chronic Low Back Pain
Princeton, New Jersey and Lund, Sweden — 29 September 2016 — Braeburn Pharmaceuticals and Camurus announce that the first patients have been enrolled in the randomized, double blind, placebo controlled Phase 3 efficacy and safety trial of CAM2038 in patients with moderate to severe chronic low back pain that are currently being treated with opioids. CAM2038 is a long-acting injectable medication with flexible dosing designed for either weekly or monthly administration. The results of this study will demonstrate whether CAM2038 can provide around-the-clock pain relief. The current standard